NGNE
Neurogene Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.60
+2.63%Sep 4, 2026, 20:01 UTC
Neurogene Inc. granted non-qualified stock options to purchase 38,330 shares of common stock to two new employees as inducement grants on September 1, 2026.
Source:Aug 11, 2026, 11:30 UTC
Neurogene Inc. announced its second quarter 2026 financial results and provided corporate updates, including positive long-term Phase 1/2 data for its NGN-401 program.
Source:Aug 11, 2026, 00:00 UTC
Neurogene Inc. completed an oversubscribed financing raising approximately $144 million in gross proceeds, with net proceeds of approximately $134.8 million from a July 2026 public offering.
Jul 2, 2026, 00:00 UTC
Neurogene Inc. entered into an underwriting agreement to issue common shares and pre-funded warrants in an underwritten public equity offering, with expected net proceeds of approximately $134.8 million.
Jun 8, 2026, 11:30 UTC
Neurogene Inc. completed dosing in the Embolden registrational trial of NGN-401 gene therapy for Rett syndrome.
Source: